Transforming mammography with AI-driven insights.
Grade: C — Score: 55/100
CureMetrix utilizes cutting-edge AI technology to analyze mammography images, providing radiologists with enhanced tools for accurate breast cancer detection. Their algorithms are designed to assist in identifying potential abnormalities that may be missed during traditional readings.
The platform integrates seamlessly into existing workflows, allowing radiologists to receive AI-generated insights without disrupting their established processes. This ensures that healthcare providers can maintain efficiency while benefiting from the added precision of AI analysis.
While the technology offers significant advantages, there are inherent risks associated with reliance on AI in medical diagnostics. It is crucial for healthcare professionals to remain vigilant and use AI as a supplementary tool rather than a replacement for their expertise.
CureMetrix cmAngio: Custom quote
Consider switching to Zebra Medical Vision: Both companies provide AI solutions for medical imaging, but Zebra focuses on a broader range of imaging modalities.
No. CureMetrix cmAngio detects and localizes breast arterial calcifications as an incidental finding on screening mammograms, but its result should not be used alone to make a diagnosis or treatment decision. The interpreting physician decides whether the finding should be reported and whether further evaluation is appropriate.
Yes. CureMetrix cmAngio version 1.6 received FDA 510(k) clearance K250754 in April 2025 for screening mammograms, covering FFDM and DBT For Presentation exams from supported Hologic and GE acquisition systems. The finalized product research records use in women aged 40 to 90.
No. CureMetrix cmAngio is designed for breast arterial calcification detection and localization, not primary interpretation of mammograms for breast cancer. CureMetrix markets separate products for cancer-related triage and lesion detection, so buyers should not treat cmAngio as a substitute for those workflows or for radiologist interpretation.
CureMetrix cmAngio processes Full Field Digital Mammography and Digital Breast Tomosynthesis For Presentation screening exams from Hologic and GE acquisition systems. It works with DICOM-compliant viewers and is described as PACS agnostic. Facilities using other manufacturers, diagnostic exams, or alternative image views need written confirmation that their workflow is within the cleared and supported scope.
No. CureMetrix cmAngio analyzes the same screening mammogram already acquired for breast-cancer screening, so the BAC analysis does not require another imaging visit, procedure, or radiation exposure. The software adds an AI-generated BAC result for physician review rather than changing how the mammogram is acquired.
CureMetrix reports an AUC of 0.98 across FFDM and DBT cases and documented performance across all breast densities. An AUC summarizes discrimination in a validation dataset and does not mean every result is correct or establish a cardiovascular diagnosis. Radiologists must review the marked images and scorecard within the clinical workflow.
The FDA-cleared workflow detects BAC at the study and breast level, marks suspected BAC segments for localization, and provides a scorecard for review. Public device documentation describes the clinical result as presence or absence and does not establish cleared severity categorization. Buyers should distinguish research scoring publications from the claims authorized for the deployed commercial version.
CureMetrix describes cmAngio as a cloud-based, PACS-agnostic system that works with DICOM-compliant viewers. Its published architecture shows eligible DICOM studies being staged and anonymized through a local cmEdge client and transmitted to the cmAngio cloud using encrypted transport. The public materials do not resolve customer export, deletion, or model-training rights, so those terms should be confirmed in the contract.
CureMetrix documents a four-week implementation covering workflow discovery, technical configuration, reporting templates, patient communications, staff education, testing, and clinical sign-off. The imaging organization must decide how radiologists document BAC, how patients and referring physicians are notified, and which primary-care or cardiology follow-up pathway applies. There is no single national BAC reporting and management standard documented by the vendor.
CureMetrix cmAngio is narrowly focused on BAC detection and localization, with a reported AUC of 0.98 across FFDM and DBT. Transpara Detection and Lunit INSIGHT DBT focus on breast-cancer detection and reading efficiency; the finalized research records Transpara processing more than 13 million mammograms and Lunit assigning 0 to 100 abnormality scores with key-slice highlighting. Those products address a different clinical gap and do not replace a dedicated BAC reporting workflow.
How AI agents (ChatGPT, Perplexity, Claude, others) read this review page in the past 7 days. Updated weekly. View CureMetrix AI Visibility Report.